IN2015KN00416A - - Google Patents

Info

Publication number
IN2015KN00416A
IN2015KN00416A IN416KON2015A IN2015KN00416A IN 2015KN00416 A IN2015KN00416 A IN 2015KN00416A IN 416KON2015 A IN416KON2015 A IN 416KON2015A IN 2015KN00416 A IN2015KN00416 A IN 2015KN00416A
Authority
IN
India
Prior art keywords
pfs47
mosquito
gambiae
falciparum
parasites
Prior art date
Application number
Inventor
Carolina Veronica Barillas-Mury
CRUZ Alvaro MOLINA
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of IN2015KN00416A publication Critical patent/IN2015KN00416A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The inventors have identified Pfs47, a gene from the malaria parasite P. falciparum, as a key factor for survival of these parasites in the mosquito Anopheles gambiae. A. gambiae is a major natural vector of human malaria in Africa. The Pfs47 protein may allow the parasite to survive in the mosquito by manipulating the mosquito s immune system. The inventors propose the use of P47 proteins, including Pfs47 and Pvs47 as a target of vaccines or pharmaceutical agents that will block or reduce P. falciparum or P. vivax infection in A. gambiae or other anopheline mosquitoes and thus prevent further transmission of the parasites in humans.
IN416KON2015 2012-08-17 2013-08-16 IN2015KN00416A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261684333P 2012-08-17 2012-08-17
PCT/US2013/055372 WO2014028852A1 (en) 2012-08-17 2013-08-16 Use of p47 from plasmodium falciparum (pfs47) or plasmodium vivax (pvs47) as a vaccine or drug screening targets for the inhibition of human malaria transmission

Publications (1)

Publication Number Publication Date
IN2015KN00416A true IN2015KN00416A (en) 2015-07-17

Family

ID=50101528

Family Applications (1)

Application Number Title Priority Date Filing Date
IN416KON2015 IN2015KN00416A (en) 2012-08-17 2013-08-16

Country Status (6)

Country Link
US (1) US20150203547A1 (en)
EP (1) EP2885410A4 (en)
CN (1) CN104736710A (en)
BR (1) BR112015003184A2 (en)
IN (1) IN2015KN00416A (en)
WO (1) WO2014028852A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157083A1 (en) 2017-02-24 2018-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for blocking transmission of plasmodium

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1423405A4 (en) * 2001-03-26 2005-01-05 Us Army Plasmodium falciparum ama-1 protein and uses thereof
US8444996B2 (en) * 2008-10-01 2013-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia
US9422348B2 (en) * 2011-10-04 2016-08-23 Statens Serum Institut Production of a cysteine rich protein

Also Published As

Publication number Publication date
EP2885410A1 (en) 2015-06-24
BR112015003184A2 (en) 2018-05-08
US20150203547A1 (en) 2015-07-23
CN104736710A (en) 2015-06-24
EP2885410A4 (en) 2016-03-23
WO2014028852A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
MD3718565T2 (en) Respiratory virus vaccines
EP3408392A4 (en) Rna guided eradication of human jc virus and other polyomaviruses
MD4733C1 (en) Anti-TIGIT antibodies
IN2014CN04187A (en)
MX2014004814A (en) Compounds and methods for enhancing innate immune responses.
WO2016210384A3 (en) Bacteria engineered to treat metabolic diseases
WO2017066706A8 (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
WO2006115843A3 (en) Nipah virus vaccines
WO2018193063A3 (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
WO2015052543A3 (en) Malaria vaccination
EA201790507A1 (en) METHODS AND COMPOSITIONS FOR STRENGTHENING IMMUNE RESPONSES
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
EA201300132A1 (en) PHARMACEUTICAL COMPOSITION AND METHODS OF TREATMENT AND PREVENTION OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
PH12017500156A1 (en) Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
GEP20197052B (en) Hyr1-derived compositions and methods of treatment using same
PH12015502844A1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
WO2012078051A3 (en) IPN Vaccine
WO2014140166A3 (en) Vaccine
WO2013108272A3 (en) Blood stage malaria vaccine
NZ606563A (en) Bacterial ghosts for mediating innate immunity
IN2014DN09445A (en)
IN2015KN00416A (en)
GB201112587D0 (en) Vaccine